Annual Survival Rate Statistics Update—Multiple Myeloma Rate Unchanged
New observational data from the United States National Cancer Institute’s Surveillance, Epidemiology, and End Results…
Browsing: Multiple Myeloma News
Stand Up To Cancer Takes New Approach to Multiple Myeloma, Focusing on Precursor Conditions
Originally seen on Markets Insider. Stand Up To Cancer announced a $10 million award to…
40 Genes that Can be Disrupted in Early Stages of Multiple Myeloma
The most recent issue of the journal Leukemia summarizes the results of a study completed…
Selinexor Gets FDA Fast-Track Status for Penta-Refractory Myeloma Patients
Karyopharm Therapeutics recently announced that their oral drug selinexor (Selective Inhibitor of Nuclear Export) is…
Making Myeloma Drugs More Targeted and Effective Using Actinium Warhead Enabling (AWE) Technology
At the recent American Association for Cancer Research (AACR) annual meeting in Chicago, Actinium Pharmaceuticals…
Myeloma 101: FISH Testing in Myeloma
FISH testing (fluorescence in situ hybridization) is a way of testing myeloma genetics in individual…
Researchers Suggest Increased Screening of MGUS Patients to Prevent Multiple Myeloma
Should we be screening the general population to learn more about how to prevent multiple…
Patient Power: New Treatment Strategies for High-Risk Patients
We know that myeloma specialists use today’s available treatments to personalize therapy for their patients.…
How To Reduce Infections During Myeloma Stem Cell Transplant
Supportive care during stem cell transplant typically includes the use of strong antibiotics like ciprofloxacin…
New Drug Targeting WT1 Found to Be Effective as Post-Transplant Myeloma Therapy for High-Risk Patients
Treating high-risk multiple myeloma is a challenge and new drugs are being developed to address…
Molecule (IL-18) Helps Myeloma Hide from the Immune System and Predicts Worse Survival
Inflammation that promotes tumor growth and the ability to hide from the immune system are…
March 12 – March 31: For Every Purchase Made, AmazonSmile Will Give 1.5% Back to Myeloma Crowd
For all purchases made between March 12 – 31, Amazon will give 1.5% of your…
Armored CAR-T Cells
A few weeks ago, we posted an interview with Sattva Neelapu, MD from MD Anderson…
Experts Weigh In On the Use of Liquid Biopsies
We have all been looking forward to the use of liquid biopsies so we can…
Long-Term Follow-Up of MGUS Patients
An interesting article was published in the New England Journal of Medicine last month that…
What Dana Farber Researchers are Learning from the PCrowd Smoldering Myeloma and MGUS Study
The Dana Farber Center for Prevention of Progression of Blood Cancers study (PCrowd) for smoldering…
Using Selinexor with Daratumumab and Dexamethasone for Relapsed or Refractory Myeloma Patients
Cristina Gasparetto, MD recently shared information about a new drug combination for relapsed and refractory…
New Test for Daratumumab (Darzalex) Patients Helps With M-Protein Accuracy
All myeloma patients are familiar with immunofixation tests (typically abbreviated as IFE, for Immmuno Fixation…
Family Genetic Mutations Linked to Multiple Myeloma Risk
Multiple myeloma has historically not been considered an “inheritable” disease. But myeloma researchers at the…
Using Light To Eliminate Multiple Myeloma at Washington University
To hear Washington University researchers speak on this topic, register for the Myeloma Crowd Round…
Celgene To Acquire Juno Therapeutics for CAR T Cell Myeloma Therapies
Celgene Corporation and Juno Therapeutics today announced a merger agreement in which Celgene will acquire…
Adding Busulfan to Melphalan for Myeloma Stem Cell Transplant Lengthens Remissions
Stem cell transplant remains the single most powerful therapy for multiple myeloma, but many patients…
Overall Survival Results for Kyprolis ASPIRE Myeloma Study Released
Kyprolis (carfizomib) is a proteasome inhibitor that is is FDA approved to be used in…
Experts’ Picks: The Best Of ASH (The American Society Of Hematology) in Summary
The American Society of Hematology (ASH) meeting is the largest meeting of experts in the…
C-Reactive Protein (Inflammation) Levels Before Transplant Can Indicate Overall Myeloma Survival
Mayo Clinic researchers have found a connection between c-reactive protein levels (a blood test marker…
FDA Approves Denosumab Bone Strengthener for Myeloma Patients
Amgen’s new bone strengthener denosumab (XGEVA®) received FDA approval today for patients with multiple myeloma…
Multiple Myeloma Word of the Day: APRIL
We will have to get used to APRIL as the new acronym to remember, and…
Janssen Oncology Jumps Into Myeloma BCMA CAR T Field in Collaboration With Chinese Firm Legend Bio
Janseen Biotech announced today that it is entering into a worldwide collaboration and license agreement…
UK Approves Ninlaro (ixazomib) for Use with Lenalidomide and Dex
Getting new myeloma drugs approved in the UK is no easy task. An organization called the…
ASH 2017: Expert’s Picks – Selinexor
I asked some of the world’s best myeloma specialists what they considered to be their…
ASH 2017: Experts’ Pick – GlaxoSmithKlein’s BCMA Antibody
ASH (The American Society Of Hematology) is the world’s most comprehensive hematology event of 2017,…
ASH 2017: Expert’s Picks – Daratumumab Treatment in Smoldering Myeloma
I asked some of the world’s best myeloma specialists what they considered to be their…
ASH 2017: Experts’ Picks – Daratumumab with Revlimid, Velcade and Dex
ASH (American Society of Hematology) is the largest and most comprehensive hematology meeting this year.…
ASH 2017: Whether it’s Newly Diagnosed Myeloma or Considered “Smoldering,” Get After It Early
In an ASH session titled “Controversies in Myeloma” Dr. Ola Landgren reviewed the data on…
ASH 2017: Computer-Generated Cancer Treatment Options are Getting Personal
Using computers to analyze our genetics and myeloma’s complex characteristics is not new, but a…
ASH 2017: Second Line Therapy to Deepen Responses Before Transplant Provides Worse Outcomes Than Just Going to Transplant Immediately
The current standard of care for myeloma patients who are transplant-eligible is to use a…
ASH 2017: Experts’ Pick – Crowdsourcing For Improved Classification Of High Risk Myeloma Patients
ASH (The American Society Of Hematology) is the world’s most comprehensive hematology event of 2017,…
ASH 2017: Tandem Transplant Better than Single Transplant in European Studies, Especially for High Risk Patients
Stem cell transplant continues to be the single most effective therapy in the treatment of…
ASH 2017: Myeloma Experts’ Favorite ASH Abstract Pick by Dr. Paul Richardson – Celgene/Bluebird Bio CAR T
ASH (The American Society Of Hematology) is the world’s most comprehensive hematology event of 2017,…
ASH 2017: Practical Aspects of Implementing CAR T Therapy for Blood Cancer Patients
The story of CAR-T, which burst onto the scene in 2013, continues to build with…
ASH 2017: Myeloma Experts’ Favorite ASH Abstract Pick by Dr. Ola Landgren
I asked some of the world’s best myeloma specialists what they considered to be their…
ASH 2017: Myeloma Experts’ Favorite ASH Abstract Pick by Dr. Saad Usmani
The upcoming American Society of Hematology meeting is the largest meeting of experts in the…
We Did it! Together, Patients and Experts Helped the Myeloma Crowd Research Initiative Exceed Our $500,000 Goal for High Risk Myeloma Research
In 2015 the Myeloma Crowd had a hypothesis: If patients collaborated with myeloma experts, we…
ASH 2017: Myeloma Experts’ Favorite ASH Abstract Pick by Dr. Vincent Rajkumar
The upcoming American Society of Hematology meeting is the largest meeting of experts in the…
Christmas Shopping on Amazon? Sign Up for AmazonSmile, and Amazon Will Donate to Myeloma Crowd
Shopping on Amazon this Christmas? Don’t forget to register for AmazonSmile to support the Myeloma…
ASH 2017: Myeloma Experts’ Favorite ASH Abstract Pick by Dr. Gareth Morgan
The upcoming American Society of Hematology meeting is the largest meeting of experts in the…
ASH 2017: Changes in Blood BCMA Antigen Levels Rapidly Indicate Changes in Clinical Status Among Multiple Myeloma Patients Undergoing New Treatments
BCMA is not just a drug target anymore, for while the B-Cell Maturation Antigen (BCMA)…
ASH 2017: Actinium Labeled Daratumumab Shows Enhanced Killing of Myeloma Cells over Naked Daratumumab
A new therapeutic approach of “turbo-charging” daratumumab (Darzalex), the monoclonal antibody drug that targets the…
Adaptive’s Next Generation Sequencing Tool Used in Myeloma Clinical Trial to Track Minimal Residual Disease Status
Adaptive Biotechnologies, maker of the Next Generation Sequencing (NGS)-based clonoSEQ test, is joining Amgen and…
ASH 2017: Darzalex (daratumumab) Moves Towards the Newly Diagnosed Myeloma Setting
This month, Janssen Biotech announced that it submitted an FDA application for the use of…